

Gyeong Sin Park

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7050210/publications.pdf>

Version: 2024-02-01

54
papers

852
citations

623734

14
h-index

501196

28
g-index

57
all docs

57
docs citations

57
times ranked

1311
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic Progression of Precancerous Actinic Keratosis to Squamous Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2022, 142, 528-538.e8.	0.7	20
2	Comparison of FDG PET/CT and Bone Marrow Biopsy Results in Patients with Diffuse Large B Cell Lymphoma with Subgroup Analysis of PET Radiomics. <i>Diagnostics</i> , 2022, 12, 222.	2.6	8
3	The RNA signature of immune-related genes and distinct spatial distribution of immune cells are closely associated with the treatment outcomes in the malignant melanoma patients receiving immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21504-e21504.	1.6	0
4	Abstract LB139: The RNA signature of immune-related genes and distinct spatial distribution of immune cells are closely associated with the treatment outcomes in the malignant melanoma patients receiving immune checkpoint inhibitors. <i>Cancer Research</i> , 2022, 82, LB139-LB139.	0.9	0
5	Lymphoepithelioid variant of peripheral T cell lymphoma (Lennert lymphoma): Cytologic and histologic features. <i>Diagnostic Cytopathology</i> , 2021, 49, 322-324.	1.0	1
6	The therapeutic efficacy of mesenchymal stromal cells on experimental colitis was improved by the IFN- γ and poly(I:C) priming through promoting the expression of indoleamine 2,3-dioxygenase. <i>Stem Cell Research and Therapy</i> , 2021, 12, 37.	5.5	25
7	Emerging Role of Consolidative Radiotherapy After Complete Remission Following R-CHOP Immunochemotherapy in Stage III-IV Diffuse Large B-Cell Lymphoma: A Single Institutional and Case-Matched Control Study. <i>Frontiers in Oncology</i> , 2021, 11, 578865.	2.8	1
8	Preclinical evaluation of JAK1/2 inhibition by ruxolitinib in a murine model of chronic graft-versus-host disease. <i>Experimental Hematology</i> , 2021, 98, 36-46.e2.	0.4	8
9	Lack of Association between <i>Chlamydomyces psittaci</i> and Ocular Adnexal MALT Lymphoma in Korean Patients-Is the Geographic or Genetic Difference Significant?. <i>Diagnostics</i> , 2021, 11, 2069.	2.6	1
10	Early Interim Chemotherapy Response Evaluation by F-18 FDG PET/CT in Diffuse Large B Cell Lymphoma. <i>Diagnostics</i> , 2020, 10, 1002.	2.6	2
11	FDG PET/CT Findings of Castleman Disease Assessed by Histologic Subtypes and Compared with Laboratory Findings. <i>Diagnostics</i> , 2020, 10, 998.	2.6	7
12	CXCR4 Inhibition Enhances Efficacy of FLT3 Inhibitors in FLT3-Mutated AML Augmented by Suppressed TGF- β 2 Signaling. <i>Cancers</i> , 2020, 12, 1737.	3.7	8
13	CCL1 blockade alleviates human mesenchymal stem cell (hMSC)-induced pulmonary fibrosis in a murine sclerodermatous graft-versus-host disease (Scl-GVHD) model. <i>Stem Cell Research and Therapy</i> , 2020, 11, 254.	5.5	7
14	A machine-learning expert-supporting system for diagnosis prediction of lymphoid neoplasms using a probabilistic decision-tree algorithm and immunohistochemistry profile database. <i>Journal of Pathology and Translational Medicine</i> , 2020, 54, 462-470.	1.1	6
15	Predictive Value of Interim and End-of-Therapy 18F-FDG PET/CT in Patients with Follicular Lymphoma. <i>Nuclear Medicine and Molecular Imaging</i> , 2019, 53, 263-269.	1.0	12
16	Accelerated Bone Regeneration via Three-Dimensional Cell-Printed Constructs Containing Human Nasal Turbinate-Derived Stem Cells as a Clinically Applicable Therapy. <i>ACS Biomaterials Science and Engineering</i> , 2019, 5, 6171-6185.	5.2	13
17	Fibrogenic effects of crocidolite, amosite, and chrysotile asbestos fibers on lung fibroblasts. <i>Toxicological and Environmental Chemistry</i> , 2019, 101, 148-164.	1.2	3
18	Comparative pathologic analysis of mediastinal B-cell lymphomas: selective expression of p63 but no GATA3 optimally differentiates primary mediastinal large B-cell lymphoma from classic Hodgkin lymphoma. <i>Diagnostic Pathology</i> , 2019, 14, 133.	2.0	12

#	ARTICLE	IF	CITATIONS
19	Enhanced Anti-Leukemic Effects through Induction of Immunomodulating Microenvironment by Blocking CXCR4 and PD-L1 in an AML Mouse Model. <i>Immunological Investigations</i> , 2019, 48, 96-105.	2.0	18
20	Role of F-18 FDG PET/CT in non-conjunctival origin ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphomas. <i>EJNMMI Research</i> , 2019, 9, 99.	2.5	3
21	Escape from thymic deletion and anti-leukemic effects of T cells specific for hematopoietic cell-restricted antigen. <i>Nature Communications</i> , 2018, 9, 225.	12.8	6
22	Ex Vivo Generated Human Cord Blood Myeloid-Derived Suppressor Cells Attenuate Murine Chronic Graft-versus-Host Diseases. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2381-2396.	2.0	11
23	Intracranial relapse as a solitary mass of ocular adnexal lymphoma of the mucosa-associated lymphoid tissue type. <i>Korean Journal of Internal Medicine</i> , 2018, 33, 224-227.	1.7	2
24	Mesenchymal Stem Cells (MSCs) Attenuate Cutaneous Sclerodermatous Graft-Versus-Host Disease (Scl-GVHD) through Inhibition of Immune Cell Infiltration in a Mouse Model. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1895-1904.	0.7	34
25	Cutaneous epithelioid hemangioendothelioma on the sole mimicking a pyogenic granuloma. <i>Australasian Journal of Dermatology</i> , 2017, 58, e150-e152.	0.7	0
26	Shift of EMT gradient in 3D spheroid MSCs for activation of mesenchymal niche function. <i>Scientific Reports</i> , 2017, 7, 6859.	3.3	26
27	CD34 + tumours of the orbit including solitary fibrous + tumours: a six-case series. <i>BMC Ophthalmology</i> , 2017, 17, 59.	1.4	11
28	Epstein-Barr Virus-Associated Lymphoproliferative Disorders: Review and Update on 2016 WHO Classification. <i>Journal of Pathology and Translational Medicine</i> , 2017, 51, 352-358.	1.1	67
29	Induction of Indoleamine 2,3-dioxygenase by Pre-treatment with Poly(I:C) May Enhance the Efficacy of MSC Treatment in DSS-induced Colitis. <i>Immune Network</i> , 2016, 16, 358.	3.6	16
30	First reported case of interferon-alpha-induced sarcoidosis in an Asian patient with malignant melanoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, e347-e349.	1.1	6
31	Role of follow-up endoscopic examination in treatment response assessment for patients with gastric diffuse large B cell lymphoma. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1111-1117.	1.5	2
32	MYC overexpression correlates with MYC amplification or translocation, and is associated with poor prognosis in mantle cell lymphoma. <i>Histopathology</i> , 2016, 68, 442-449.	2.9	34
33	Diffuse Large B-Cell Lymphoma of the Peri-Implant Mucosa Mimicking Peri-Implantitis. <i>Journal of Oral Implantology</i> , 2016, 42, 220-223.	1.0	4
34	BIS-mediated STAT3 stabilization regulates glioblastoma stem cell-like phenotypes. <i>Oncotarget</i> , 2016, 7, 35056-35070.	1.8	21
35	Analysis of treatment outcomes for primary tonsillar lymphoma. <i>Radiation Oncology Journal</i> , 2016, 34, 273-279.	1.5	8
36	Attenuation of Hepatic Graft-versus-host Disease in Allogeneic Recipients of MyD88-deficient Donor Bone Marrow. <i>Immune Network</i> , 2015, 15, 125.	3.6	4

#	ARTICLE	IF	CITATIONS
37	Long-term Outcome of Extranodal NK/T Cell Lymphoma Patients Treated With Postremission Therapy Using EBV LMP1 and LMP2a-specific CTLs. <i>Molecular Therapy</i> , 2015, 23, 1401-1409.	8.2	63
38	A CXCR4 antagonist leads to tumor suppression by activation of immune cells in a leukemia-induced microenvironment. <i>Oncology Reports</i> , 2015, 34, 2880-2888.	2.6	18
39	Bis Expression in Patients with Surgically Resected Lung Cancer and its Clinical Significance. <i>Annals of Surgical Oncology</i> , 2015, 22, 1365-1370.	1.5	4
40	Differential Effect of MyD88 Signal in Donor T Cells on Graft-versus-Leukemia Effect and Graft-versus-Host Disease after Experimental Allogeneic Stem Cell Transplantation. <i>Molecules and Cells</i> , 2015, 38, 966-974.	2.6	7
41	Liquid-based cytology in the fine needle aspiration of parathyroid lesions: a comparison study with the conventional smear, ThinPrep, and SurePath. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 12160-8.	0.5	7
42	Clinicopathological Features of Rare <i>BRAF</i> Mutations in Korean Thyroid Cancer Patients. <i>Journal of Korean Medical Science</i> , 2014, 29, 1054.	2.5	33
43	Gestational Loss and Growth Restriction by Angiogenic Defects in Placental Growth Factor Transgenic Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 2276-2282.	2.4	18
44	A paradoxical pattern of indoleamine 2,3-dioxygenase expression in the colon tissues of patients with acute graft-versus-host disease. <i>Experimental Hematology</i> , 2014, 42, 734-740.	0.4	7
45	Modeling de novo leukemogenesis from human cord blood with MN1 and NUP98HOXD13. <i>Blood</i> , 2014, 124, 3608-3612.	1.4	23
46	Cell Fate Decisions in Malignant Hematopoiesis: Leukemia Phenotype Is Determined by Distinct Functional Domains of the MN1 Oncogene. <i>PLoS ONE</i> , 2014, 9, e112671.	2.5	15
47	MN1 Inhibits Myeloid Differentiation by Transcriptional Repression of EGR2. <i>Blood</i> , 2010, 116, 229-229.	1.4	1
48	Functional Role of BAALC In Leukemogenesis. <i>Blood</i> , 2010, 116, 4194-4194.	1.4	0
49	Competition In Engraftment of Normal Hematopoietic Stem Cells and Leukemic Stem Cells. <i>Blood</i> , 2010, 116, 4836-4836.	1.4	0
50	Incidence and Clinical Outcome of Intestinal Thrombotic MicroAngiopathy (TMA) in Patients Suspected to Clinical Graft Versus Host Disease (GVHD).. <i>Blood</i> , 2007, 110, 1976-1976.	1.4	0
51	IL10-Transduced Mesenchymal Stem Cells Attenuate Experimental Acute Graft-Versus-Host Disease.. <i>Blood</i> , 2005, 106, 5247-5247.	1.4	0
52	High Level CD24 Expression Is Correlated to Higher Metastatic Potential of Breast Cancer Cells.. <i>Blood</i> , 2004, 104, 2859-2859.	1.4	0
53	A Case of Primary Pulmonary Sarcoma with Morphologic Features of Malignant Fibrous Histiocytoma. <i>Tuberculosis and Respiratory Diseases</i> , 2002, 52, 186.	0.2	0
54	Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. <i>Oncogene</i> , 1999, 18, 3754-3760.	5.9	249